Menu Search
Equities

Cidara Therapeutics Inc

20D:DUS

Cidara Therapeutics Inc

Actions
  • Price (EUR)0.4596
  • Today's Change-8.73 / -95.00%
  • Shares traded2.00k
  • 1 Year change-98.10%
  • Beta--
Data delayed at least 15 minutes, as of Apr 23 2024 18:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

  • Revenue in USD (TTM)63.91m
  • Net income in USD-22.93m
  • Incorporated2012
  • Employees69.00
  • Location
    Cidara Therapeutics Inc6310 Nancy Ridge Dr Ste 101SAN DIEGO 92121-3209United StatesUSA
  • Phone+1 (858) 752-6170
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cidara.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.